In recent years, lots of studies showed that PPARα agonists exert therapeutic effects against ocular degenerative disorders with effects on anti-inflammatory, anticoagulant, anti-apoptosis, anti-oxidation and inhibition of neovascularization (Deng et al., 2017; He et al., 2020; Nakano et al., 2020; Nakano et al., 2020), while PPARα−/− mice with diabetes manifest more severe retinal acellular capillaries (Moran et al., 2014; Qiu et al., 2017). This evidence concerns the gene PPARA and diabetes mellitus.